CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About CADTH What We Do Programs and Services CADTH Reimbursement Review Elosulfase alfa

Elosulfase alfa

Last Updated: October 1, 2015

Result type: Reports

Project Number: SR0456-000

Product Line: Reimbursement Review

Generic Name: Elosulfase alfa

Brand Name: Vimizim

Manufacturer: BioMarin Pharmaceutical (Canada) Inc.

Therapeutic Area: Mucopolysaccharidosis IVA (Morquio A syndrome)

Indications: Mucopolysaccharidosis IVA (Morquio A syndrome)

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: May 20, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions

Elosulfase alfa

Files